title: [Pharmacological and clinical profiles of nalfurafine hydrochloride (Remitch) capsules 2.5 microg) , a new therapeutic agent for the treatment of uremic pruritus in hemodialysis patients].
authors.forename: Kaoru
authors.initials: K
authors.lastname: Nakao
authors.forename: Akihiro
authors.initials: A
authors.lastname: Ando
authors.forename: Mikito
authors.initials: M
authors.lastname: Hirakata
authors.forename: Naoki
authors.initials: N
authors.lastname: Ando
authors.forename: Koichiro
authors.initials: K
authors.lastname: Takeshita
authors.forename: Yohei
authors.initials: Y
authors.lastname: Miyamoto
authors.forename: Hidenori
authors.initials: H
authors.lastname: Mochizuki
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002214:Capsules; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009019:Morphinans / Q000008:administration & dosage* / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D011537:Pruritus / Q000188:drug therapy* / Q000209:etiology*; D011957:Receptors, Opioid / Q000819:agonists / Q000378:metabolism; D006435:Renal Dialysis / Q000009:adverse effects*; D013141:Spiro Compounds / Q000008:administration & dosage* / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D014511:Uremia / Q000150:complications*
chemical_list: D002214:Capsules; D009019:Morphinans; D011957:Receptors, Opioid; D013141:Spiro Compounds; C111212:TRK 820